|Bid||0.6750 x 1800|
|Ask||0.6898 x 800|
|Day's Range||0.6730 - 0.6900|
|52 Week Range||0.4850 - 2.7700|
|Beta (5Y Monthly)||2.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.